Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (August 13, 2026) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, today

Event · Earnings
Original reporting
Published Aug 13, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 11:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$INDP
Neutral
medium confidence
Mentioned
$INDP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$INDPNeutralMed
01

Why it matters

Traders can update models for cash runway and dilution expectations using the disclosed $12.0M financing and the stated liquidity position, while also reassessing pipeline risk given Decoy20 discontinuation and lack of active clinical programs.

02

Market read

Liquidity improved via a priced equity raise, but the clinical pipeline is effectively paused, making the stock sensitive to any future strategic transaction or new clinical/regulatory catalysts.

03

What to watch

The company may still pursue a post-investment transaction, but the timeline and terms are unspecified; dilution risk from potential future financings remains a key overhang.

Relevance 7/10Novelty 8/10Timing: filed pre-market today (Aug 13, 2026) with Q2 results and financing details

Background

Indaptus filed an 8-K with its Q2 2026 financial results and corporate update, including a June 2026 private placement and a strategic review of its Decoy platform.

Company-level read

Ticker impact

$INDPNeutralMedium confidence
Context

Indaptus completed a $12.0M private placement at $0.60/share and reported Q2 cash of $7.6M plus $4.0M short-term investments.

Expected impact

Near-term bias depends on whether the market values the liquidity extension versus the clinical de-risking; expect volatility around dilution and strategic-review headlines.

Evidence & confidence

The article discloses concrete financing terms, updated cash/short-term investments, and a discontinuation of Decoy20 enrollment with no active clinical development programs, which typically drives both dilution concerns and re-rating of pipeline risk.

Market effects

Small-cap biotech investors may reprice risk for immunotherapy platforms when clinical programs are discontinued and replaced by strategic reviews.

Limited direct regional spillover; primarily affects Nasdaq small-cap biotech sentiment.

Low global relevance; the story is company-specific and financing/pipeline focused.

Counterpoint

The liquidity boost and shift to neurological disorders and sleep collaboration could be viewed as a strategic pivot rather than a setback, supporting a valuation floor.

Key entities

  • Indaptus Therapeutics, Inc.

    Nasdaq-listed biotech that reported Q2 2026 results, completed a $12.0M private placement, and discontinued Decoy20 enrollment.

  • Decoy20

    Combination study referenced as having enrollment discontinued, with no remaining participants and no active clinical development programs.

  • Junyi Dai

    CEO and Chairman who discussed balance-sheet strengthening, strategic alternatives, and a new research collaboration in neurological disorders and sleep.

Related articles

$INDPMed

Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (November 13, 2026) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, toda

$INDPMedAI 8/10

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics (Nasdaq: INDP) reported Q2 2026 results and a corporate update. It raised about $12.0 million via a June 17 private placement at $0.60 per share. The company discontinued further Decoy20 enrollment and has no active clinical programs. Q2 R&D fell to ~$0.4M and net loss to ~$1.8M. Cash and short-term investments were ~$11.6M at June 30.

$CISSMedAI 8/10

C3is (CISS) Q3 2026 Earnings Call Transcript

C3is (CISS) reported Q3 2026 earnings, with voyage revenues up 249% YoY to $16.7M and nine-month revenues up 116% to $52.4M. Adjusted net income increased 1,300% YoY to $13.2M. Cash balance rose 335% to $64.9M. The company expanded its fleet and secured time charters for bulk carriers. Management highlighted strong market demand for iron ore, coal, and grain, driving shipping rates.

$NVDAHighAI 9/10

What's Going On With Nvidia Stock Wednesday

Nvidia (NVDA) reported quarterly earnings of $2.68 per share on revenue of $115.84 billion, beating estimates. Data center sales reached $107.6 billion. The company raised its revenue forecast for the current quarter and long-term growth outlook, but expects no revenue from China. Nvidia also expanded its stock buyback program.